Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers

#2910

Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.

Aim(s): In our current preclinical work of virotherapy on neuroendocrine cancer using a panel of human NET/NEC (neuroendocrine tumor/neuroendocrine carcinoma) cell lines we employed a HSV-1 based vector named T-VEC (IMLYGIC™), which is the only EMA/FDA virotherapeutic compound approved, but so far only for advanced stages of melanoma.

Materials and methods: Oncolytic properties of T-VEC were demonstrated with the SRB cell viability assay. Virus transgene expression could be observed using the LEGEND MAX™ Human GM-CSF ELISA. Viral replication patterns were studied by sequential virus quantification. Moreover, a combinatorial treatment with the mTOR inhibitor everolimus was assessed by a real-time cell monitoring.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Lauer U

Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,

Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,